MWMegan Work

Megan Work

*This is an algorithmically generated author record based on publicly available information.

Megan Work has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • High T‐cell lymphoma of the vulva in a female dog

    by Valentina Silic, Megan Work, Naomi Earley, Slavomíra Néčová

    Extra‐nodal lymphoma of the female genital system in dogs is extremely rare. In this case report, we describe a case of genital lymphoma with involvement of the regional lymph nodes in a 10‐year‐old, female, neutered Samoyed. Dog presented with a 4‐week history of an oedematous and erythematous vulva. Additionally, on clinical examination, popliteal and inguinal lymphadenomegaly and a right‐sided vulvar mass were detected. Cytology of the popliteal lymph node and vulvar mass revealed a monomorphic population of large lymphocytes; flow cytometry performed on the enlarged lymph nodes confirmed the diagnosis of high‐grade T‐cell lymphoma. Due to worsening of the clinical signs and concerns regarding quality of life, the owners elected for euthanasia while the results were pending. This is an unusual presentation of T‐cell lymphoma of the vulva and regional lymph nodes and represents an important differential diagnosis for oedema of external genitals and local lymphadenomegaly in female dogs.

  • Top Cited Papers
    Open Access

    Retrospective study and outcome of 307 cats with feline infectious peritonitis treated with legally sourced veterinary compounded preparations of remdesivir and GS-441524 (2020–2022)

    by Samantha S Taylor, Sally Coggins, Emi N Barker, Danièlle Gunn-Moore, Kamalan Jeevaratnam, Jacqueline M Norris, David Hughes, Emily Stacey, Laura MacFarlane, Carolyn O’brien, et al.

    Objectives: Feline infectious peritonitis (FIP) is a serious disease that arises due to feline coronavirus infection. The nucleoside analogues remdesivir and GS-441524 can be effective in its treatment, but most studies have used unregulated products of unknown composition. The aim of the present study was to describe the treatment of FIP using legally sourced veterinary-prescribed regulated veterinary compounded products containing known amounts of remdesivir (injectable) or GS-441524 (oral tablets). Methods: Cats were recruited via email advice services, product sales contacts and study publicity. Cats were excluded if they were deemed unlikely to have FIP, were not treated exclusively with the veterinary compounded products, or if there was a lack of cat and/or treatment (including response) data. Extensive cat and treatment data were collected. Results: Among the 307 cats recruited, the predominant type of FIP was most commonly abdominal effusive (49.5%) and then neurological (14.3%). Three treatment protocols were used; remdesivir alone (33.9%), remdesivir followed by GS-441524 (55.7%) and GS-441524 alone (10.4%). The median (range) initial treatment period duration and longest follow-up time point after starting treatment were 84 (1–330) days and 248 (1–814) days, respectively. The most common side effect was injection pain (in 47.8% of those given subcutaneous remdesivir). Of the 307 cats, 33 (10.8%) relapsed, 15 (45.5%) during and 18 (54.5%) after the initial treatment period. At the longest follow-up time point after completion of the initial treatment period, 84.4% of cats were alive. The cats achieving a complete response within 30 days of starting treatment were significantly more likely to be alive at the end of the initial treatment period than those cats that did not. Conclusions and relevance: Legally sourced remdesivir and GS-441524 products, either alone or used sequentially, were very effective in the treatment of FIP in this group of cats. Variable protocols precluded statistical comparison of treatment regimens.


  • A survey on Shar Pei autoinflammatory disease in the United Kingdom

    by M. Work, C. Scudder, K. Bergum Hjellegjerde, M. Dunning, I. Gajanayake, A. Kent, L. Tintle, T. Sparks, F. Allerton

    Objectives: To characterise the fever episodes attributed to Shar Pei autoinflammatory disease and to identify common diagnostic and management strategies in the United Kingdom. A secondary objective was to determine risk factors associated with Shar Pei autoinflammatory disease fever episodes.Methods: A retrospective survey was performed to characterise episodes of Shar Pei autoinflammatory disease fever and to identify commonly used treatments in affected dogs. Clinical data were collected from owners and veterinarians. Frequencies of previously proposed risk factors (skin thickness and folding, muzzle conformation) and comorbid conditions were compared between dogs that had exhibited fever episodes consistent with Shar Pei autoinflammatory disease and those who had not.Results: At least one episode of fever attributed to Shar Pei autoinflammatory disease was reported in 52 of 106 (49%) Shar Pei. Nine other dogs had fever episodes consistent with Shar Pei autoinflammatory disease reported by their owners but not by veterinarians. Median rectal temperature at presentation for Shar Pei autoinflammatory disease fever was 40.1°C [104.2°F] (39.9 to 41.3°C [103.8 to 106.3°F]) and owners reported associated hyporexia (n=33, 63%) and vomiting (n=8, 15%) more frequently than veterinary records (n=22, 42% and n=0, 0%, respectively). The median number of veterinary appointments for Shar Pei autoinflammatory disease was two per dog (1 to 15) while owners reported a median of four episodes per dog per year. None of the assessed phenotypic variants or comorbidities were significantly associated with exhibiting Shar Pei autoinflammatory disease fever episodes.Clinical Significance: Episodes of Shar Pei autoinflammatory disease fever were reported approximately twice as frequently by owners compared to veterinary records, suggesting the burden of this condition may be underestimated by veterinarians. Specific risk factors for Shar Pei autoinflammatory disease fever were not identified.


  • Percutaneous‐endoscopic rendezvous cholangiography with biliary stent placement in a dog with extra‐hepatic biliary duct obstruction

    by M. Work, F. Allerton, S. Griffin, A. Kent

    A middle‐aged male springer spaniel was presented for investigation of acute vomiting, lethargy and icterus. Marked distension of the gall bladder and common bile duct was evident at ultrasound due to obstruction by mineralised intraluminal material. After 48 hours of hospitalisation with intravenous fluid therapy, analgesia and antimicrobial therapy, intervention was deemed necessary to relieve the obstruction. A percutaneous‐endoscopic rendezvous approach was used to achieve placement of a pigtail stent into the distal common bile duct, successfully relieving the obstruction. Serial biochemistry measurements postprocedure confirmed marked improvements in serum bilirubin. The patient remains clinically well 24 months postprocedure, and all hepatic enzyme activities have normalised. Based on the literature search performed, this is the first successful application of this technique in the management of canine extrahepatic biliary duct obstruction.